Dyne Therapeutics Statistics
Total Valuation
DYN has a market cap or net worth of $1.15 billion. The enterprise value is $516.33 million.
Important Dates
The next estimated earnings date is Thursday, May 1, 2025, after market close.
| Earnings Date | May 1, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
DYN has 113.12 million shares outstanding. The number of shares has increased by 57.74% in one year.
| Current Share Class | 113.12M |
| Shares Outstanding | 113.12M |
| Shares Change (YoY) | +57.74% |
| Shares Change (QoQ) | +1.09% |
| Owned by Insiders (%) | 0.30% |
| Owned by Institutions (%) | 90.00% |
| Float | 97.28M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.86 |
| P/TBV Ratio | 1.80 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 15.60, with a Debt / Equity ratio of 0.04.
| Current Ratio | 15.60 |
| Quick Ratio | 15.20 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -88.03% and return on invested capital (ROIC) is -55.64%.
| Return on Equity (ROE) | -88.03% |
| Return on Assets (ROA) | -50.20% |
| Return on Invested Capital (ROIC) | -55.64% |
| Return on Capital Employed (ROCE) | -52.99% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.66M |
| Employee Count | 191 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -59.82% in the last 52 weeks. The beta is 1.11, so DYN's price volatility has been higher than the market average.
| Beta (5Y) | 1.11 |
| 52-Week Price Change | -59.82% |
| 50-Day Moving Average | 13.29 |
| 200-Day Moving Average | 28.63 |
| Relative Strength Index (RSI) | 38.48 |
| Average Volume (20 Days) | 1,832,053 |
Short Selling Information
The latest short interest is 12.38 million, so 10.95% of the outstanding shares have been sold short.
| Short Interest | 12.38M |
| Short Previous Month | 11.67M |
| Short % of Shares Out | 10.95% |
| Short % of Float | 12.73% |
| Short Ratio (days to cover) | 7.74 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -343.89M |
| Pretax Income | -257.40M |
| Net Income | -317.42M |
| EBITDA | -342.21M |
| EBIT | -343.89M |
| Earnings Per Share (EPS) | -$3.37 |
Full Income StatementBalance Sheet
The company has $642.27 million in cash and $23.99 million in debt, giving a net cash position of $618.28 million or $5.47 per share.
| Cash & Cash Equivalents | 642.27M |
| Total Debt | 23.99M |
| Net Cash | 618.28M |
| Net Cash Per Share | $5.47 |
| Equity (Book Value) | 629.84M |
| Book Value Per Share | 6.16 |
| Working Capital | 617.02M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$292.37 million and capital expenditures -$2.38 million, giving a free cash flow of -$294.75 million.
| Operating Cash Flow | -292.37M |
| Capital Expenditures | -2.38M |
| Free Cash Flow | -294.75M |
| FCF Per Share | -$2.61 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |